MS-DRG 825 is a Medicare Severity Diagnosis Related Group for "LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC". DRGs are used by Medicare to classify hospital cases into groups for payment purposes. Each DRG has a payment weight based on the average resources used to treat patients in that group.

How many hospitalizations were there for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC in 2023?

There were 442 Medicare hospitalizations classified under MS-DRG 825 in 2023. This represents a -1.8% change from 2022.

What is the average cost for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC?

The average hospital charges for MS-DRG 825 were $72,173 in 2023. Note that charges represent what hospitals bill, which is typically higher than what Medicare actually pays.

How have hospitalizations for this DRG changed over time?

Medicare hospitalization data for MS-DRG 825 is available from 2013 to 2023. The charts above show the historical trends in hospitalizations and average charges over this period.

MS-DRG 825

LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC

Hospitalizations (2023)

442

-1.8%vs 2022

Average Charges (2023)

$72,173

+5.3%vs 2022

Hospitalization Trends

Average Charges

Frequently Asked Questions

Related ICD-10 Codes

This MS-DRG is associated with 519 ICD-10-CM diagnosis codes:

C26.1Malignant neoplasm of spleen

C46.3Kaposi's sarcoma of lymph nodes

C77.0Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck

C77.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes

C77.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes

C77.3Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes

C77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes

C77.5Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes

C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions

C77.9Secondary and unspecified malignant neoplasm of lymph node, unspecified

C7B.01Secondary carcinoid tumors of distant lymph nodes

C81.00Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site

C81.01Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck

C81.02Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes

C81.03Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes

C81.04Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb

C81.05Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

C81.06Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes

C81.07Nodular lymphocyte predominant Hodgkin lymphoma, spleen

C81.08Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites

Back to DRG Statistics

Data source: CMS Medicare Inpatient Hospitals, Centers for Medicare & Medicaid Services (CMS).

MS-DRG 825

What is MS-DRG 825?

How many hospitalizations were there for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC in 2023?

What is the average cost for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC?

How have hospitalizations for this DRG changed over time?

MS-DRG 825

What is MS-DRG 825?

How many hospitalizations were there for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC in 2023?

What is the average cost for LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC?

How have hospitalizations for this DRG changed over time?